Navigation Links
Interleukin Genetics Reports First Quarter 2009 Financial Results
Date:5/14/2009

ion for the three months ended March 31, 2009, compared to $2.1 million for same period in the prior year. The decrease was primarily attributable to reduced expenses related to consulting partially offset by increased advertising and promotional expenses plus increased expenses relating to increased headcount.

The Company reported a net loss of $2.5 million, or $(0.08) per basic and diluted common share, for the first quarter of 2009, compared to $1.9 million, or $(0.06) for the same period in the prior year. On March 31, 2009, the Company reported cash and cash equivalents of $1.7 million. In addition, the Company has access to $10.3 million under credit facilities with Alticor.

2009 Highlights to Date

Corporate Highlights

  • Granted License of Heart Health Genetic Test to LABEC Pharma. In April, the Company entered into a licensing agreement to permit LABEC Pharma to market and sell the Company's Heart Health genetic test throughout Spain and Portugal. As part of the agreement, the tests will be processed at Interleukin Genetics and marketed by LABEC Pharma. Interleukin Genetics will receive royalties and commercial milestone payments.
  • Improved Genetic Test Format. In March, Interleukin Genetics announced the creation of a new, detailed report format and information package for its General Nutrition genetic risk assessment test to enable a better understanding of an individual's genetic pattern as it relates to vitamin B metabolism and response to oxidative stress and free radicals.

Research Highlights

  • Presented Data Linking Vertebral Fractures to Gene Variations. Interleukin Genetics presented research findings from a large clinical study on the genetics of osteoporosis and vertebral fractures at the 8th International Symposium on Os
    '/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
2. Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
3. Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
4. Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
5. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
6. Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
7. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
8. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
9. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
10. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
11. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:U.S. Cancer Cases, Deaths Continue to Drop 2Health News:U.S. Cancer Cases, Deaths Continue to Drop 3Health News:U.S. Cancer Cases, Deaths Continue to Drop 4Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 2Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 3Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 4Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 5Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 2Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 3Health News:Genetic variations indicate risk of recurrence, secondary cancer among head and neck cancer patients 2Health News:Anthem Blue Cross and Blue Shield in Maine and National Council on Aging Provide Vital Benefits Information to Economically Challenged Older Adults 2
Breaking Medicine Technology:Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7EntreMed Reports Second Quarter 2009 Financial Results 53818 1EntreMed Reports Second Quarter 2009 Financial Results 53818 2EntreMed Reports Second Quarter 2009 Financial Results 53818 3EntreMed Reports Second Quarter 2009 Financial Results 53818 4SXC Health solutions announces record second quarter financial results 53815 1SXC Health solutions announces record second quarter financial results 53815 2SXC Health solutions announces record second quarter financial results 53815 3SXC Health solutions announces record second quarter financial results 53815 4SXC Health solutions announces record second quarter financial results 53815 5SXC Health solutions announces record second quarter financial results 53815 6SXC Health solutions announces record second quarter financial results 53815 7SXC Health solutions announces record second quarter financial results 53815 8SXC Health solutions announces record second quarter financial results 53815 9SXC Health solutions announces record second quarter financial results 53815 10SXC Health solutions announces record second quarter financial results 53815 11SXC Health solutions announces record second quarter financial results 53815 12SXC Health solutions announces record second quarter financial results 53815 13SXC Health solutions announces record second quarter financial results 53815 14SXC Health solutions announces record second quarter financial results 53815 15SXC Health solutions announces record second quarter financial results 53815 16SXC Health solutions announces record second quarter financial results 53815 17SXC Health solutions announces record second quarter financial results 53815 18SXC Health solutions announces record second quarter financial results 53815 19Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 1Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 2Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 3Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 4Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 5Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 6Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 7Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 8